67 results about "Immunohistochemistry" patented technology

The invention belongs to the technical field of medical diagnosis, and discloses a quantum multicolor immune digital pathological diagnosis analysis system, which comprises the following steps: acquiring high-resolution digital images of an immunohistochemical or immunofluorescence slice and a slide, and analyzing multicolor signal distribution in the images to obtain a quantum chromatographic image set; pixel-level color separation and intensity quantization are carried out on the quantum chromatographic image set, and a quantum intensity index set of each pixel is generated; performing multi-target color overlay analysis and post-translational modification protein specificity evaluation on the quantum intensity index set to construct a multi-color modification index set; identifying a single cell boundary and a multi-cell community based on the multicolor modification index set, and extracting a cell morphological parameter and a spatial adjacency relation to obtain a cell quantum analysis set; performing consistency correction and traceable recording by applying an automatic quality control mechanism, and generating a digital diagnosis report; the accuracy of accurate qualitative and quantitative analysis of immunohistochemistry and immunofluorescence is greatly improved.

An oncological foundation model is trained with broad, multimodal data to make predictions concerning a variety of different types of cancers. For example, the foundation model may make use of medical images drawn from radiology and pathology, as well as immunohistochemistry data; the presence or absence of biomarkers for particular diagnoses; patient history data; patient demographic data; and other forms of medical data. When using medical images, whole medical images as well as feature sets derived from the medical images may be used. The foundation model may have both causal predictive abilities as well as generative abilities.

Methods and systems for analysing the cellular composition of a sample are described, comprising: providing an image of the sample in which a plurality of cellular populations are associated with respective signals and classifying a plurality of query cells in the image between a plurality of classes corresponding to respective cellular populations in the plurality of cellular populations. This is performed by providing a query single cell image to an encoder module of a machine learning model to produce a feature vector for the query image, and assigning the query cell to one of the plurality of classes based on the feature vector for the query image and feature vectors produced by the encoder module for each of a plurality of reference single cell images. The machine leaning model comprises: the encoder module, configured to take as input a single cell image and to produce as output a feature vector the single cell image, and a similarity module configured to take as input a pair of feature vectors for a pair of single cell images and to produce as output a score indicative of the similarity between the single cell images. Thus, the machine learning model can be obtained without the need for an extensively annotated dataset. The methods find use in the analysis of multiplex immunohistochemistry / immunofluorescence in a variety of clinical contexts.

This invention discloses a breast cancer classification method based on Piezo1 expression. After obtaining tumor tissue samples from patients, the method detects the Piezo1 protein expression level using immunohistochemistry and classifies them into high-expression and low-expression types according to a validated scoring standard. This classification result guides individualized treatment, with high-expression patients recommended for treatment regimens including inhibitors of mechanotransmission pathways. By integrating tumor mechanotransmission characteristics into the clinical classification system, this invention can identify a subgroup of breast cancer driven by an abnormal mechanotransmission microenvironment that cannot be distinguished by traditional molecular classification. This not only improves and supplements the existing classification framework, making the understanding of breast cancer heterogeneity more comprehensive, but also more accurately predicts the invasiveness, metastasis potential, and poor prognostic risk of these patients.

Microglial spatial heterogeneity remains a crucial yet poorly studied question in light of potential cell-directed therapies for Alzheimer`s disease (AD). Little is known about the dynamics of spatially distinct microglia states, which are either adjacent or non-associated with the plaque site, and their selective contributions to neurodegeneration in vivo. So far, research has essentially focused on pathology-associated microglia. Here, we combined novel multicolor fluorescence fate mapping, single-cell transcriptional analysis, epigenetic profiling, advanced immunohistochemistry and computational modelling to comprehensively characterize the relation of plaque-associated and non-plaque- associated microglia during neurodegeneration. This approach enabled us to identify and characterize non-plaque-associated microglia as a unique and highly dynamic microglial state in a mouse model of AD. Non-plaque-associated microglia modulate network expansion, quickly adapt to environmental cues and their transition to plaque-associated microglia can be specifically modulated during disease, contrary to their reputation as a passive bystander subpopulation. This description of the dynamics of spatially segregated microglial states and their distinct molecular features may therefore open promising new avenues for state-specific therapeutic interventions during neurodegeneration.

1. Name of the product in this design: Fully Automatic Immunohistochemistry Independent Temperature Controlled Individual Drop Staining Machine (CNT310). 2. Purpose of this design: For staining samples before pathological analysis. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The present application relates to the technical field of incubation bin assembly, and aims to provide an incubation bin liquid discharge device and an immunohistochemical device to solve the technical problem of low liquid discharge efficiency of the incubation bin in the prior art, which affects incubation and reaction operation. The immunohistochemical device comprises a bottom plate and an incubation bin assembled on the bottom plate, and further comprises an incubation bin liquid discharge device assembled on the bottom plate, wherein the incubation bin liquid discharge device is connected with the incubation bin in correspondence, and the incubation bin liquid discharge device comprises a transfer bin and a liquid discharge channel connected at one end of the transfer bin, the other end of the liquid discharge channel is provided with a liquid inlet, and the liquid inlet is used for butting against a waste liquid pipe at the bottom of the incubation bin; a quick liquid discharge device is connected on the liquid discharge channel or the transfer bin, and the quick liquid discharge device is used for sucking the transfer bin to quickly suck the waste liquid in the waste liquid bin into the transfer bin.

This invention discloses an anti-MSLN antibody and its applications. The anti-MSLN antibody comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3. The amino acid sequences of HCDR1, HCDR2, and HCDR3 are shown in SEQ ID NO:7, 8, and 9, respectively; and the amino acid sequences of LCDR1, LCDR2, and LCDR3 are shown in SEQ ID NO:4, 5, and 6, respectively. The antibody provided by this invention has good affinity and specificity for MSLN antigens, effectively detecting target proteins in cells overexpressing MSLN. It can also be widely used as a core ingredient in the development of high-sensitivity MSLN detection kits such as ELISA, Western blotting, and immunohistochemistry.

This invention discloses the application of arginine-depleted engineered bacteria for the treatment of soft tissue sarcomas, including preliminary validation, obtaining qualified engineered bacteria SGR1, obtaining drug compositions and regimens, experimental conclusions, and clinical application promotion. During use, clinical soft tissue sarcoma samples are collected, including undifferentiated pleomorphic sarcoma, synovial sarcoma, and liposarcoma. Immunohistochemistry (IHC) is used to detect ASS1 protein expression, qPCR is used to detect ASS1 gene transcription levels, and the proportion of ASS1 deletion / low expression is statistically analyzed. Arginine auxotrophic sarcoma subpopulations are confirmed based on literature. Cells are cultured in arginine-containing or arginine-free media, and cell viability, colony formation, cell cycle, and apoptosis are detected. The sensitivity of ASS1-deficient cells to arginine deprivation is verified, and therapeutic targets are identified. The enzyme activity, substrate specificity, and immunogenicity of human ARG I / II, mycoplasma ADI, and Pseudomonas ADI are compared. High-activity, low-immunogenic enzymes or enzyme combinations (such as human ARG I + microbial ADI) are selected, and site-directed mutagenesis or codon optimization is performed on microbial ADI to increase expression levels.

The application provides a construction method of a humanized keloid mouse model, comprising the following steps: BAC plasmid construction and preparation; superovulation of experimental mice and collection of zygotes; pronuclear microinjection of zygotes; post-injection embryo transplantation; genotype identification; breeding and genetic analysis; and verification of construction results of the humanized immune system by immunohistochemistry and immunofluorescence. In the application, peripheral blood mononuclear cells treated by sCD27 and skin around keloids (homologous cells and tissues) are transplanted into NSG-MHC-DKO immune-deficient mice with overexpression of CD70 genes, so that HLA rejection of different homologous immune cells and tissues can be avoided, the internal microenvironment of keloids and the interaction between the internal microenvironment and the immune system can be restored to the maximum extent, and the influence of immune factors on the occurrence and development of keloids can be realized in vitro. The application first discovers and verifies that the activation of the CD27-CD70 axis can promote the occurrence and development of keloids, and provides a suitable animal model for the research and development of anti-keloid drugs, especially immunotherapy.

This invention discloses DLL3 as a therapeutic target for cervical neuroendocrine carcinoma and its application, belonging to the field of biotechnology. This invention discloses the specific expression of the DLL3 gene in cervical neuroendocrine carcinoma (NECC) and its application as a therapeutic target. Single-cell sequencing and immunohistochemistry revealed activation of the DLL3-NOTCH1 / 2 signaling axis in NECC, and functional experiments confirmed that it drives malignant progression by promoting tumor proliferation and inducing T cell exhaustion. Furthermore, this invention constructed an NECC organoid-TIL co-culture model to verify the synergistic efficacy of the DLL3-targeting drug AMG757 combined with EP chemotherapy. This invention provides new target selection and theoretical basis for the precision diagnosis and treatment of NECC, and has significant clinical translational value.

The application discloses a kind of detection Tgfβ1 to hepatolenticular degeneration neutrophil polarization method and application, including the following steps: step 1, by immunohistochemistry and immunofluorescence co-localization determine hepatolenticular degeneration mouse liver fibrosis formation process, hepatocyte high expression Tgfβ1;Step 2, by inhibiting the high expression of Tgfβ1 of hepatolenticular degeneration mouse liver fibrosis formation process, determine the mitigation of neutrophil polarization;Step 3, collect mouse bone marrow neutrophil, by real-time fluorescence quantitative PCR, protein electrophoresis and methylation reaction determine the mechanism of Tgfβ1 promote neutrophil polarization.The application can detect the effect of Tgfβ1 in hepatolenticular degeneration neutrophil polarization, facilitate to determine hepatolenticular degeneration liver lesion mechanism.

Immunohistochemistry (INC) and in situ hybridization (ISH) methods are used for the targeted detection and localization of biomolecules (e.g., proteins and miRNAs) in tissues or cells, for research applications and clinical applications such as those of pathologists (e.g., biomarker analysis of resected tumors or tumor biopsies). These methods include mass spectrometry imaging (MSI) as a mode for detecting and localizing biomolecules in tissues or cells. The methods employ optically cleavable mass-tagged reagents linked to probes such as antibodies and nucleic acids and used to enable multiplexed immunohistochemistry and in situ hybridization, with MSI as the detection / readout mode. The methods also include multi-omics MSI procedures in which MSI of optically cleavable mass-tagged probes is combined with other MSI modes, such as direct label-free MSI of endogenous biomolecules from biological samples (e.g., tissues).

This invention discloses an anti-MSLN antibody and its applications. The anti-MSLN antibody comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3. The amino acid sequences of HCDR1, HCDR2, and HCDR3 are shown in SEQ ID NO:7, 8, and 9, respectively; and the amino acid sequences of LCDR1, LCDR2, and LCDR3 are shown in SEQ ID NO:4, 5, and 6, respectively. The antibody provided by this invention has good affinity and specificity for MSLN antigens, effectively detecting target proteins in cells overexpressing MSLN. It can also be widely used as a core ingredient in the development of high-sensitivity MSLN detection kits such as ELISA, Western blotting, and immunohistochemistry.

This invention belongs to the field of biomedicine and tumor immunotherapy technology, specifically relating to a monoclonal antibody targeting the immune checkpoint molecule CD276 (B7-H3) and its applications. The applicant conducted immunization and screening work around the human CD276 antigen, selecting two representative monoclonal antibody clones, 2B2-1 and 5G4-2, from multiple candidate antibodies. The nucleotide and amino acid sequences of their heavy and light chain variable regions were determined, and their performance in flow cytometry, T-cell killing assays, immunohistochemistry, ELISA, and Biacore affinity assays was systematically evaluated. Experimental results show that the above antibodies can specifically recognize and bind to CD276, efficiently distinguish between CD276-high and low-expressing cells, and enhance the killing activity of T cells against CD276-high expressing tumor cells in an in vitro co-culture system. This provides an excellent antibody backbone for the subsequent construction of diagnostic kits, ADC drugs, or bispecific antibodies.

The invention relates to the technical field of medical image processing and artificial intelligence, and particularly discloses an intestinal cancer pathological image screening method applied to fluorescence immunohistochemistry. The method comprises the following steps: carrying out multi-channel acquisition and pretreatment on a fluorescent pathological section; according to the method, the image screening model based on the convolutional neural network is constructed and trained, automatic screening and grading of pathological images are realized through the trained deep learning model, mass fluorescence immunohistochemical intestinal cancer pathological images can be processed in batches, manual evaluation one by one is not needed, the screening period is greatly shortened, and the screening efficiency is improved. The problems that traditional manual screening is low in efficiency and difficult to meet high-throughput image analysis requirements are solved. According to the automatic process, the workload of pathologists is reduced, fatigue errors caused by long-time manual screening are avoided, efficient and stable data screening support is provided for subsequent accurate quantitative analysis and AI model training, and efficient promotion of clinical pathological research and diagnosis is assisted.

An oncological foundation model is trained with broad, multimodal data to make predictions concerning a variety of different types of cancers. For example, the foundation model may make use of medical images drawn from radiology and pathology, as well as immunohistochemistry data; the presence or absence of biomarkers for particular diagnoses; patient history data; patient demographic data; and other forms of medical data. When using medical images, whole medical images as well as feature sets derived from the medical images may be used. The foundation model may have both causal predictive abilities as well as generative abilities.

The application discloses a goat recombinant monoclonal antibody against rabbit IgG and a preparation and application thereof, and belongs to the technical field of biotechnology. The recombinant monoclonal antibody is obtained by taking purified rabbit serum IgG as an immunogen, immunizing a goat, screening specific B cells, and obtaining a heavy chain variable region and a light chain variable region of the antibody through RT-PCR. The variable region sequences are respectively inserted into a vector plasmid with constant region (heavy chain and light chain) genes, and the recombinant monoclonal antibody is obtained through transfection expression and purification. The recombinant monoclonal antibody provided in the application has high affinity with rabbit IgG, can recognize and detect rabbit IgG with high specificity and high sensitivity, and can be used as a secondary antibody after HRP cross-linking, applied to methods such as protein immunoblotting, immunohistochemistry and ELISA for detecting rabbit IgG, is conducive to obtaining more accurate detection and evaluation results, and reduces the interference of detection cost and background signal.

The application provides an incubation device for immunohistochemistry, a staining treatment all-in-one machine and a control method thereof. The device comprises a cabin body, a carrier and a condensation flow guide plate. The carrier is provided with a humidification flow channel, which is divided into multiple liquid accumulation pools by a liquid distribution baffle, and the overflow principle is used to ensure uniform humidity and inhibit liquid accumulation during movement. The condensation flow guide plate is provided with a heating surface and a condensation surface, the temperature of the condensation surface is controlled to be lower than the dew point, vapor is induced to condense on the condensation surface and is discharged to a waste liquid outlet through the flow guide surface, and condensate droplets are prevented from falling on the slide. A driving assembly drives the carrier to move between an incubation position and an operation position and drives the cabin door to move. The application combines zoned temperature control, induced condensation and physical directional flow guidance, solves the risk of sample dilution caused by random condensation of condensate in a high humidity environment, simplifies the overall structure of the machine and improves the automation integration degree.

This invention discloses the application of P4HB as a target in the preparation of therapeutic drugs for metastatic pleural and peritoneal effusions in multiple cancer types. Through combined single-cell transcriptomics and proteomics analysis, this invention revealed that P4HB is significantly overexpressed in metastatic pleural and peritoneal effusion lesions. Multiplex immunofluorescence and immunohistochemistry were used to perform in situ tissue validation in clinical samples of pleural and peritoneal effusions from breast cancer, lung cancer, gastric cancer, colorectal cancer, and ovarian cancer, clarifying the differential expression characteristics of P4HB in metastatic tumor cells and its correlation with poor prognosis. In patient-derived organoid models, targeting and inhibiting P4HB activity with small molecule inhibitors significantly reduced organoid growth capacity and survival rate, and showed a synergistic sensitizing effect on chemotherapeutic drugs. This invention reveals the use of P4HB as a therapeutic target for metastatic pleural and peritoneal effusions in multiple cancer types, providing a new target and direction for drug development in precision medicine.

The invention relates to the field of biological medicine, in particular to a lactic dehydrogenase LDHB protein 196-site serine phosphorylation antibody as well as a preparation method and application thereof. On the basis of the 196-site serine phosphorylated polypeptide of the lactic dehydrogenase LDHB protein, the 196-site serine phosphorylated antigen and antibody of the lactic dehydrogenase LDHB protein are prepared, and a preparation method of the 196-site serine phosphorylated antibody of the lactic dehydrogenase LDHB protein is provided. The prepared lactic dehydrogenase LDHB protein 196-site serine phosphorylated antibody can be used for detecting low-abundance LDHB Ser196 signals, is suitable for various detection platforms such as Western blot and immunohistochemistry, and meets the detection requirements of tumor tissue samples.

The invention discloses application of neensinine in prevention and treatment of endometriosis, the neensinine is used as a traditional Chinese medicine monomer, the neensinine is used for preventing and treating the endometriosis, and the neensinine can resist fibrosis of the endometriosis so as to play a role in prevention and treatment. A mouse endometriosis model is constructed through an allotransplantation method, after four weeks of successful modeling, a modeling mouse model group, a dienogest control group and a neferine group are respectively taken for four weeks, and then laparotomy is performed to take out ectopic lesions. HE staining and masson staining methods are used for mutual evidence of fibrosis degree, immunohistochemical detection of fibrosis index a-SMA expression conditions is carried out, and Western-blot detection of fibrosis-related protein expression levels: FN, CTGF, alpha-SMA and COL-I. Therefore, the neferine can be potentially developed into drugs for treating or preventing fibrosis of endometriosis in the future.

The application discloses a PET tracer targeting carbonic anhydrase IX (CA IX) and a preparation method and application thereof. 68 The tracer is prepared from a DOTA-bis-sulfonamide precursor compound and GaCl3 reaction. The tracer has high hydrophilicity, excellent stability in vitro and in vivo, low uptake of non-target organs and is mainly excreted through the kidney. Micro-PET / CT imaging shows that the tumor uptake is linearly correlated with the CA IX protein expression level measured by immunohistochemistry. Acute toxicity experiments show that the tracer has good biological safety. The application further provides a radiopharmaceutical composition containing the tracer and application of the tracer in preparation of a PET imaging agent for diagnosing CA IX positive tumors. The tracer has the advantages of high labeling efficiency, low background interference, accurate quantification and potential integration of diagnosis and treatment, and is suitable for precise molecular imaging of CA IX high expression tumors such as clear cell renal cell carcinoma and colorectal cancer.

The invention discloses a standardized NMOSD animal model construction method and drug screening application, a female Lewis rat of 6-8 weeks old is selected, Asian race high pathogenicity AQP4-IgG is injected into the female Lewis rat through a spinal cord sheath built-in tube, the female Lewis rat is continuously administered for five days, and the pathogenicity of the model is verified through behavioral scoring, immunohistochemistry and Western Blot. The rat model is easy and convenient to operate, glucocorticoid treatment resistance phenotypes can be stably simulated, the core pathological indexes are highly consistent with those of clinical refractory NMOSD patients, and drug screening application covers grouping intervention, multi-dimensional evaluation and quantitative judgment. The method overcomes the defects that an existing model is poor in repeatability, insufficient in race specificity and the like, a standardized tool is provided for NMOSD mechanism research and targeted drug research and development, and the application value is remarkable.

A method for synthesizing an IHC image based on a histological image of a tissue sample is disclosed. A computer-implemented system generates a first input specifying at least a portion of the histological image and processes the first input using a predictive neural network to generate a predicted score indicative of an expression level of a molecular marker. The system further processes a second input comprising data specifying the predicted score using a generative neural network to generate a synthetic IHC image characterizing a spatial distribution of the molecular marker within the tissue sample. The generative neural network has been trained with a discriminator neural network, the generative neural network and the discriminator neural network being constituent parts of a conditional generative adversarial network (cGAN), the cGAN being conditional to the predicted score.

The application provides a non-small cell lung cancer prediction method based on PD-L1 immunohistochemical staining, relates to the field of artificial intelligence, and comprises the following steps: S1, multi-modal original data acquisition and preprocessing; S2, intra-modal feature enhancement and structured modeling; S3, non-Euclidean space feature mapping; S4, multi-modal feature fusion and interactive modeling; and S5, immunotherapy response prediction. The method takes PD-L1 immunohistochemistry as a necessary core input, supports flexible integration of other multi-modal data, adaptively processes the differences and missing problems of modalities, accurately captures multi-dimensional information association, realizes adaptive multi-modal data fusion prediction, and improves the accuracy and clinical applicability of the prediction of the immunotherapy benefit of a non-small cell lung cancer patient.

This application relates to the field of antibody technology, and discloses a CRP immunohistochemical antibody and its application. The antibody includes a heavy chain variable region and a light chain variable region. Combinations of the heavy chain variable region and the light chain variable region include: Combination 1: the heavy chain variable region contains the amino acid sequence shown in SEQ ID NO:2, and the light chain variable region contains the amino acid sequence shown in SEQ ID NO:4; or Combination 2: the heavy chain variable region contains the amino acid sequence shown in SEQ ID NO:6, and the light chain variable region contains the amino acid sequence shown in SEQ ID NO:8. The antibody of this application achieves precise localization by recognizing tumor cell-specific CRP conformations or post-translational modification epitopes. It specifically recognizes CRP expressed by tumor cells, completely avoiding interference from serum CRP and non-specific deposition in necrotic areas, and exhibits no background staining in normal tissues.

The application provides a rat TEX264 recombinant protein, a recombinant vector, a polyclonal antibody and application, and relates to the technical field of biological engineering.The amino acid sequence of the rat TEX264 recombinant protein is shown as SEQ ID NO.2.The application provides a preparation method of an anti-rat TEX264 polyclonal antibody, and a polyclonal antibody against rat TEX264 is prepared; the antibody can specifically recognize endogenous TEX264 protein of a rat, and is used for experiments such as ELISA, Western Blot, immunofluorescence analysis and the like.The application provides a material basis for studying the function of TEX264.The antibody of the application can detect TEX264 protein of human and mouse tissues in addition to recognizing and detecting rat TEX264, compared with a related antibody on the market which can only detect TEX264 protein of mouse and / or human tissue samples; the antibody can simultaneously detect TEX264 protein of rat, mouse and human tissue samples, and is suitable for various different detection methods such as Western Blot, immunohistochemistry and immunofluorescence, and has advantages in economic benefits.

The application relates to the field of biological medicine, and particularly discloses a monoclonal antibody combined with human CD8 and a preparation method and application thereof. The antibody is obtained by combining single B cell sorting, gene cloning and mammalian cell expression technology after rabbit immunization of a CD8 polypeptide antigen, a New Zealand white rabbit is immunized by adopting a KLH coupled CD8 antigen polypeptide combined with a rapid immunoadjuvant, high-affinity antibody clones are obtained by single B cell sorting technology, and the antibody is prepared by recombination expression. The antibody is verified by ELISA and flow cytometry, has high titer and strong specificity, can effectively recognize human peripheral blood CD8+ T cells, and has a signal strength and a background signal-to-noise ratio which are significantly better than those of a traditional mouse-derived antibody. The application provides light and heavy chain variable region amino acid sequences of the antibody, realizes controllable preparation of the antibody and protection of intellectual property rights. The antibody can be widely applied to the fields of flow cytometry detection, immunohistochemistry, tumor immunotherapy monitoring and T cell function research, and has important scientific research and clinical application values.

The present application relates to the technical field of antibodies, in particular to anti-CD38 recombinant rabbit monoclonal antibody and application thereof.The anti-CD38 recombinant rabbit monoclonal antibody provided by the present application has high specificity and high sensitivity in combination with CD38 protein molecules, can specifically recognize and detect the expression of CD38 protein on cells, is positively highly expressed in the detection of CD38 protein, and is found through immunohistochemical detection of various different tissues that the antibody can be applied to the detection and screening fields of IHC, ELISA, immunoblotting, antibody chip preparation, flow cytometry and the like, and is favorable for obtaining accurate evaluation and detection results.Compared with the existing anti-CD38 antibody, the CD38 recombinant rabbit monoclonal antibody of the 645J4B5 clone of the present application is good in specificity, strong in positive signal and the like, is easier to score in IHC staining, is more accurate in the detection and differentiation of cancer, and is suitable for popularization and application.